The complexity and cost of vaccine manufacturing – An overview

Vaccine

Volumn 35, Issue 33, 2017, Pages 4064-4071

  Plotkin, Stanley ^a   Robinson, James M ^b   Cunningham, Gerard ^c   Iqbal, Robyn ^d   Larsen, Shannon ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Independent Consultant   (United States)

^c Founder and Principal Consultant with Innovations for Global Health (iGH)   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Gavi; Licensure; Manufacturing; Manufacturing costs; Quality; UNICEF; Vaccines; WHO, Prequalification

Indexed keywords

VACCINE;

BIOTECHNOLOGY; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; ECONOMIC DEVELOPMENT; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION; ECONOMICS; HUMAN; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES; TECHNOLOGY;

HUMANS; TECHNOLOGY TRANSFER; TECHNOLOGY, PHARMACEUTICAL; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 85021058021     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.06.003     Document Type: Review

References (24)

1. Milstien, J., Batson, A., Meaney, W., A systematic method for evaluating the potential viability of local vaccine producers. Vaccine 15 (1997), 1358–1363.
2. WHO vaccine preventable diseases: monitoring system, 2010 global summary; 2010. [accessed 17.02.07].
3. Danzon, P.M., Nicholson, S., The Oxford handbook of the economics of the pharmaceutical industry. 2012, Osford University Press, Oxford, 537.
4. Médecins Sans Frontières. The Right Shot: Bringing down barriers to affordable and adapted vaccines, 2nd ed.; 2015 [accessed 17.02.07].
5. Amie Batson. Introduction to global markets. Unpublished presentation at Global Vaccine and Immunization Research Forum; March 2016.
6. US DoD Report. on Biological Warfare Defense Vaccine Research and Development Programs; 2001. [accessed 17.02.07].
7. Robinson, J.M., Vaccine production: main steps and considerations. Bloom, B., Lambert, P.H., (eds.) The vaccine book, 2nd ed., 2016, Academic Press, San Diego, 77–96.
8. Vidor, E., Soubeyrand, B., Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Exp Rev Vaccines 15:12 (2016), 1575–1582.
9. Gerson DF, Mukherjee B. Manufacturing process development for high-volume, low-cost vaccines. BioProcess International. April 2005.
10. Pisano, G.P., The development factory: unlocking the potential of process innovation. 1996, Harvard Business School Press, Cambridge MA.
11. Gomez PL, Robinson JM, Rogalewicz JA. Vaccine Manufacturing. Vaccines, 6th ed. In: Plotkin S, Orenstien W, Offit P. Orlando, editors. WB Saunders Company; 2013. p. 44–57.
12. Interviews with industry experts.
13. Smith, J., Lipsitch, Almond, J.W., Vaccine production, distribution, access and uptake. Lancet 378:9789 (2011), 428–438.
14. Wilson P, Giving developing countries the best shot: an overview of vaccine access and R&D; 2010.
15. Bill & Melinda Gates Foundation. Production Economics for Vaccines. 2016. < https://docs.gatesfoundation.org/Documents/Production_Economics_Vaccines_2016.pdf> [accessed 17.05.05].
16. Denault JF, Coquet A, Dodelet V. Construction and start-up costs for biomanufacturing plants. BioProcess International, Feb 2008.
17. New York Times: The price of prevention: vaccine costs are soaring; 2014, July 2.
18. Mahoney, R.T., Francis, D.P., Frazatti-Gallina, N.M., Precioso, A.R., Raw, I., Watler, P., et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 30:32 (2012), 4892–4896.
19. WHO. WHO Prequalification Financing Model – Questions and Answers < http://www.who.int/medicines/news/prequal_finance_model_q-a/en/> [accessed 17.05.05].
20. [Vaccine Development CMC Benchmarking Study]. Unpublished survey data of 16 global vaccine manufacturers; 2014.
21. PATH fact sheet. Investing in Vaccines for the Developing World; 2009.
22. André, F.E., How the research-based industry approaches vaccine development and establishes priorities. Dev Biol (Basel) 110 (2002), 25–29.
23. WHO. WHO updates on regulatory system strengthening and prequalification activities; 2016. [accessed 17.02.07].
24. Sinclair A, Latham P. Vaccine production economics. In: Wen EP, Ellis R, Pujar NS, editors. Vaccine Manufacturing and Development; 2015. p. 415.